Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Our Therapies
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jess Rowlands

    Head of Corporate Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row

  • Read more about bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row

bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

  • Read more about bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio: Transforming the Treatment of Sickle Cell Disease

  • Read more about bluebird bio: Transforming the Treatment of Sickle Cell Disease

bluebird bio Completes Planned Business Separation

  • Read more about bluebird bio Completes Planned Business Separation

Najoh Tita-Reid

  • Member of the Compensation Committee
  • Member of the Nominating and Corporate Governance Committee
Najoh Tita-Reid
Director

Andrew Obenshain

    Andrew Obenshain
    Director

    Nick Leschly

      Nick Leschly
      Director

      Lis Leiderman

      • Chair of the Audit Committee
      • Member of the Compensation Committee
      Lis Leiderman
      Director
      Financial Expert

      bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

      • Read more about bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

      bluebird bio Provides Update on Upcoming Planned Business Separation

      • Read more about bluebird bio Provides Update on Upcoming Planned Business Separation

      Pagination

      • First page « First
      • Previous page ‹ Previous
      • …
      • Page 3
      • Page 4
      • Page 5
      • Page 6
      • Current page 7
      • Page 8
      • Page 9
      • Page 10
      • Page 11
      • …
      • Next page Next ›
      • Last page Last »
      Subscribe to

      Quick Links

      • Patients & Advocacy
      • Investors & Media
      • Careers
      • Contact Us

      CONTACT INFO

      info@bluebirdbio.com

      clinicaltrials@bluebirdbio.com

      investor@bluebirdbio.com

      medinfo@bluebirdbio.com

      Live - Terms & Privacy

      • Terms of Service
      • Privacy Policy
      • Cookie Notice
      • Sitemap
      © 2023 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

      Live - Social Links